This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-03 and is reviewed periodically as new material appears.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
== Medical uses == Dexrazoxane has been used to protect the heart against the cardiotoxic side effects of chemotherapeutic drugs such as anthracyclines, such as daunorubicin or doxorubicin or other chemotherapeutic agents. However, in July 2011 the European Medicines Agency (EMA) released a statement restricting use only in adult patients with cancer who have received > 300 mg/m2 doxorubicin or > 540 mg/m2 epirubicin and general approval for use for cardioprotection. That showed a possibly higher rate of secondary malignancies and acute myelogenous leukemia in pediatric patients treated for different cancers with both dexrazoxane and other chemotherapeutic agents that are associated with secondary malignancies. On 19 July 2017, based on evaluation of the currently available data the European Commission issued an EU-wide legally binding decision to implement the recommendations of the Committee for Medicinal Products for Human Use (CHMP) on dexrazoxane and lifted its 2011-contraindication for primary prevention of anthracycline-induced cardiotoxicity with dexrazoxane in children and adolescents where high doses (≥ 300 mg/m3) of anthracyclines are anticipated. Dexrazoxane was designated by the US FDA as an orphan drug for "prevention of cardiomyopathy for children and adults 0 through 16 years of age treated with anthracyclines". This decision allows virtually all children to receive dexrazoxane starting with the first dose of anthracycline at the discretion of the treating provider.
=== Moisture content of wood in service === Wood retains its hygroscopic characteristics after it is put into use. It is then subjected to fluctuating humidity, the dominant factor in determining its EMC. These fluctuations may be more or less cyclical, such as diurnal changes or annual seasonal changes. To minimize the changes in wood moisture content or the movement of wooden objects in service, wood is usually dried to a moisture content that is close to the average EMC conditions to which it will be exposed. These conditions vary for interior uses compared with exterior uses in a given geographic location. For example, according to the Australian Standard for Timber Drying Quality (AS/NZS 4787, 2001), the EMC is recommended to be 10–12% for the majority of Australian states, although extreme cases are up to 15 to 18% for some places in Queensland, Northern Territory, Western Australia and Tasmania. However, the EMC is as low as 6 to 7% in dry centrally heated houses and offices or in permanently air-conditioned buildings.
He also co-founded Animal Bioscience in 2017 along with his brother Nick. The company focuses on small molecule-based therapy for the pet industry. In the same year he founded Life Biosciences to develop gene therapies aimed at age-related disease. In 2022, Metro Biotech successfully urged the FDA to take actions to take NMN off the market as a supplement because Metro Biotech had registered NMN in investigational new drug applications. The following year, he co-founded Tally Health, a supplement company with a stated goal to "change the way we age" at the cellular level.
Cannabis had been decriminalised by the Prayut government in 2022, with the move being most supported by the Bhumjaithai Party (BJT) as one of its flagship policies. The Pheu Thai party had run in 2023 on an anti-drug policy and opposed the use of cannabis except for medical use and, under Srettha, had proposed legislation aimed at restricting the use of cannabis. The party's stance on cannabis thus led to tension with the BJT – creating a rift between the two parties which remained in a coalition when Paetongtarn became prime minister. The Thai government had hoped that decriminalising cannabis would turn it into a cash crop. A lack of laws governing cannabis were blamed for the rise in illegal distribution and the creation of a saturated market. Shortly after becoming prime minister, the Ministry of Public Health proposed a new bill on 12 September 2024 restricting cannabis to medical and research reasons. It also proposed the establishment of a Cannabis Control Board (CCB) to regulate the industry. The bill did not pass and Paetongtarn pledged that the government would not reverse its policy on cannabis again. However, by 2025, tourists smuggling cannabis out from Thailand was on the rise. Somsak Thepsuthin, the Minister of Public Health, listed in May that Hong Kong, India, Pakistan and the United Kingdom were the main destinations. On 22 May, the Paetongtarn government announced it planned to introduce new restrictions limiting cannabis usage to individuals (including foreigners) with medical prescriptions from doctors.
== Refusal == In the United States federal criminal system, refusing to take a drug test triggers an automatic revocation of probation or supervised release. In Victoria, Australia the driver of the car has the option to refuse the drug test. Refusing to undergo a drug test or refusing to undergo a secondary drug test after the first one, triggers an automatic suspension and disqualification for a period of two years and a fine of AUD$1000. The second refusal triggers an automatic suspension and disqualification for a period of four years and an even larger fine.
Sources: en.wikipedia.org
=== Reorganization and growth === In 1943, during the so-called Mantiqueira Conference, the party secretly met in the small city of Engenheiro Passos, Rio de Janeiro, and in an open letter to Vargas decided to support a declaration of war on the Axis. At the same time, Luís Carlos Prestes was elected to the party's presidency. In 1945, after Vargas's dictatorship ended, the PCB became legal once again. By 1947, it had nearly two hundred thousand members. In the 1947 legislative election, it received 480,000 votes or about 9% of total votes cast. However, this period of official tolerance did not last long, as President Dutra denounced the PCB as "internationalist, and therefore not committed to Brazil's own interests" in 1948, an action supported by the American government. In the 1950s, as the party was driven underground, it began supporting major workers' strikes around Brazil. However, this did not prevent the beginning of internal clashes between different factions within the PCB. This became more evident after the Soviet Communist Party's 20th Congress, when Nikita Khrushchev denounced Joseph Stalin's policies. The factionalization of the party accelerated after a new Manifesto was passed in 1958, proposing new ways of achieving communist goals. This Manifesto linked the establishment of socialism to the broadening of democracy. Some of its top leaders, dissatisfied with the new Soviet line, quit the PCB and formed a new party, Communist Party of Brazil (Partido Comunista do Brasil – PCdoB) in 1962. In the mid-1960s the U.S.
AAV is of particular interest to gene therapists due to its apparent limited capacity to induce immune responses in humans, a factor which should positively influence vector transduction efficiency while reducing the risk of any immune-associated pathology. AAV is not considered to have any known role in disease. However, host immune system response and immune tolerance reduce the efficacy of AAV-mediated gene therapy. Host immune response has been shown to respond to the AAV vectors, the transduced cells, and the transduced proteins. The immune response can be subdivided into two categories: innate and adaptive, the latter of which is divided into humoral and cell-mediated.
== Bibliography == Audi, G.; Kondev, F. G.; Wang, M.; et al. (2017). "The NUBASE2016 evaluation of nuclear properties" (PDF). Chinese Physics C. 41 (3) 030001. Bibcode:2017ChPhC..41c0001A. doi:10.1088/1674-1137/41/3/030001. Beiser, A. (2003). Concepts of modern physics (6th ed.). McGraw-Hill. ISBN 978-0-07-244848-1. OCLC 48965418. Hoffman, D. C.; Ghiorso, A.; Seaborg, G. T. (2000). The Transuranium People: The Inside Story. World Scientific. ISBN 978-1-78-326244-1. Kragh, H. (2018). From Transuranic to Superheavy Elements: A Story of Dispute and Creation. Springer. ISBN 978-3-319-75813-8. Silva, Robert J. (2011). "Chapter 13. Fermium, Mendelevium, Nobelium, and Lawrencium". In Morss, Lester R.; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements. Netherlands: Springer. pp. 1621–1651. doi:10.1007/978-94-007-0211-0_13. ISBN 978-94-007-0210-3. Zagrebaev, V.; Karpov, A.; Greiner, W. (2013). "Future of superheavy element research: Which nuclei could be synthesized within the next few years?". Journal of Physics: Conference Series. 420 (1) 012001. arXiv:1207.5700. Bibcode:2013JPhCS.420a2001Z. doi:10.1088/1742-6596/420/1/012001. ISSN 1742-6588. S2CID 55434734.
==== Hoji ==== Houji Tomasu (戸増 宝児, Tomasu Hōji), also known simply as "Hoji" (ホージー, Hōjī), is the professional, yet arrogant and stubborn, second-in-command and sniper of the team who serves as Deka Blue (デカブルー, Deka Burū). While he is reserved about his personal life and shows little emotion to prevent both from interfering with his work, he has a tendency to blurt out English phrases such as "Perfect!", "Unbelievable!", and "Super cool!". Due to their differing personalities, Hoji clashes with Ban early in the series, though Hoji slowly warms up to, and becomes friends with, Ban. Later in the series, Hoji applies for a gold badge promotion from the Tokkyou division, but ultimately refuses it due to a personal tragedy. In the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Hoji goes undercover as a shut-in after Doggie Kruger's seeming turn to crime to help Ban and Sen-chan restore their leader's reputation. As Deka Blue, Hoji wields the D-Knuckle (ディーナックル, Dī Nakkuru) and the D-Rod (ディーロッド, Dī Roddo) baton, which can combine to form the D-Sniper (ディースナイパー, Dī Sunaipā) rifle. He also rides the Machine Husky (マシンハスキー, Mashin Hasukī) police motorcycle. Using the D-Rod, Hoji can perform the Blue Finish (ブルーフィニッシュ, Burū Finisshu) attack. Hoji is portrayed by Tsuyoshi Hayashi (林 剛史, Hayashi Tsuyoshi).
Sources: en.wikipedia.org
7-CPP antagonist SRIF-A CyCam cyclo(7-Ahep-Phe-Trp-Lys-Thr(Bzl)) cyclo(7-aminoheptanoylphenylalanyl-tryptophyl-lysyl-benzylthreonyl) cyclo-(7-aminoheptanoyl-Phe-D-Trp-Lys-Thr(Bzl)) Cyclosomatostatin may have the possibility of treating complications of acute hemorrhage. Hepatic insulin sensitizing substance (HISS), a hormone, will be secreted by the liver which stimulates skeletal muscle glucose uptake when responding to insulin. This action makes up around 56% of total insulin action. Hemorrhage was shown to cause insulin resistance by this type of HISS-dependent insulin resistance (HDIR). Two animal studies shows that cyclosomatostatin can help prevent HDIR without correcting the hyperglycemic condition in the situation of hemorrhage and exogenous somatostatin infusion. Cyclosomatostatin may be related to other indications, including the potential of blocking the suppression of gastric emptying triggered by corticotropin-releasing hormone (CRH), the key regulator of the hypothalamic-pituitary-adrenal axis released to alter the body response caused by stress. Furthermore, cyclosomatostatin, even if used alone, may modulate neurotransmitter levels. It increases acetylcholine (ACh) release by reversing the inhibitory effect of a substance, DHP agonist Bay K 8844, to L-type voltage-sensitive Ca2+ calcium channel.
==== Alternative medicine ==== The scalp must be cleaned from sebum, sweat, and dirt, prior to topical application, for agents to penetrate it. A 2020 systemic review on agents used to treat androgenic alopecia found that:
Axonotmesis are a range of peripheral nerve injuries that are considered more severe than Neurapraxia and less severe than Neurotmesis. Axonotmesis involves loss of relative axon continuity and myelin covering, but preservation of the connective tissue framework (including encapsulating tissue, the epineurium and perineurium). Since connective tissue framework is preserved then axonal regeneration is possible, but recovery is slower. Other characteristics:
== Factors that affect the specific dynamic action == The specific dynamic action is increased by both aerobic training of sufficient duration and intensity or by anaerobic weight training. Caffeine intake at meals also has been shown to increase TEF by enhancing sympathetic arousal. However, these effects are marginal, amounting to 7-8 calories per hour. The primary determinants of daily TEF are the total caloric content of the meals and the macronutrient composition of the meals ingested. Meal frequency has little to no effect on TEF, assuming total calorie intake for the days are equivalent. Some studies suggest that SDA may be reduced in patients with obesity, especially those with insulin resistance, although research findings are mixed. A low TEF could potentially predispose to obesity by reducing energy expenditure and promoting a positive energy balance. Alternatively, the presence of a low TEF in many patients with obesity may be explained by insulin resistance, which can be related to excess dietary energy and vary in severity with the degree of obesity. Over time, chronic hyperinsulinemia could diminish the ability of cells to respond to insulin, promote adiposity and peripheral insulin resistance, and worsen the risk for type 2 diabetes. Some research shows that TEF may be more severely impaired in patients depending on the grade of insulin resistance, although some other studies have not reproduced that finding.
The convention elected a national committee of 33 members, with 22 seats for the majority caucus, 8 seats for Harrington's Coalition Caucus, 2 for the Debs caucus, and one for the "independent" Samuel H. Friedman. These minority caucuses all opposed the name change. The convention voted on and adopted proposals for its program by a two-one vote, with the majority caucus winning every vote.
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.